1
|
Imomnazarov K, Lopez-Scarim J, Bagheri I, Joers V, Tansey MG, Martín-Peña A. Biochemical Fractionation of Human α-Synuclein in a Drosophila Model of Synucleinopathies. Int J Mol Sci 2024; 25:3643. [PMID: 38612454 PMCID: PMC11011978 DOI: 10.3390/ijms25073643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 03/19/2024] [Accepted: 03/19/2024] [Indexed: 04/14/2024] Open
Abstract
Synucleinopathies are a group of central nervous system pathologies that are characterized by the intracellular accumulation of misfolded and aggregated α-synuclein in proteinaceous depositions known as Lewy Bodies (LBs). The transition of α-synuclein from its physiological to pathological form has been associated with several post-translational modifications such as phosphorylation and an increasing degree of insolubility, which also correlate with disease progression in post-mortem specimens from human patients. Neuronal expression of α-synuclein in model organisms, including Drosophila melanogaster, has been a typical approach employed to study its physiological effects. Biochemical analysis of α-synuclein solubility via high-speed ultracentrifugation with buffers of increasing detergent strength offers a potent method for identification of α-synuclein biochemical properties and the associated pathology stage. Unfortunately, the development of a robust and reproducible method for the evaluation of human α-synuclein solubility isolated from Drosophila tissues has remained elusive. Here, we tested different detergents for their ability to solubilize human α-synuclein carrying the pathological mutation A53T from the brains of aged flies. We also assessed the effect of sonication on the solubility of human α-synuclein and optimized a protocol to discriminate the relative amounts of soluble/insoluble human α-synuclein from dopaminergic neurons of the Drosophila brain. Our data established that, using a 5% SDS buffer, the three-step protocol separates cytosolic soluble, detergent-soluble and insoluble proteins in three sequential fractions according to their chemical properties. This protocol shows that sonication breaks down α-synuclein insoluble complexes from the fly brain, making them soluble in the SDS buffer and thus enriching the detergent-soluble fraction of the protocol.
Collapse
Affiliation(s)
- Khondamir Imomnazarov
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
| | - Joshua Lopez-Scarim
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
| | - Ila Bagheri
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
| | - Valerie Joers
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
| | - Malú Gámez Tansey
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
- Fixel Institute for Neurological Diseases, Department of Neurology, University of Florida, Gainesville, FL 32610, USA
| | - Alfonso Martín-Peña
- Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA; (K.I.); (J.L.-S.); (I.B.); (V.J.); (M.G.T.)
| |
Collapse
|
2
|
Imomnazarov K, Lopez-Scarim J, Bagheri I, Joers V, Tansey MG, Martín-Peña A. Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.02.05.579034. [PMID: 38370694 PMCID: PMC10871193 DOI: 10.1101/2024.02.05.579034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Synucleinopathies are a group of central nervous system pathologies that are characterized by neuronal accumulation of misfolded and aggregated α-synuclein in proteinaceous depositions known as Lewy Bodies (LBs). The transition of α-synuclein from its physiological to pathological form has been associated with several post-translational modifications such as phosphorylation and an increasing degree of insolubility, which also correlate with disease progression in postmortem specimens from human patients. Neuronal expression of α-synuclein in model organisms, including Drosophila melanogaster, has been a typical approach employed to study its physiological effects. Biochemical analysis of α-synuclein solubility via high-speed ultracentrifugation with buffers of increasing detergent strength offers a potent method for identification of α-synuclein biochemical properties and the associated pathology stage. Unfortunately, the development of a robust and reproducible method for evaluation of human α-synuclein solubility isolated from Drosophila tissues has remained elusive. Here, we tested different detergents for their ability to solubilize human α-synuclein carrying the pathological mutation A53T from brains of aged flies. We also assessed the effect of sonication on solubility of human α-synuclein and optimized a protocol to discriminate relative amounts of soluble/insoluble human α-synuclein from dopaminergic neurons of the Drosophila brain. Our data established that, using a 5% SDS buffer, the 3-step protocol distinguishes between cytosolic soluble proteins in fraction 1, detergent-soluble proteins in fraction 2 and insoluble proteins in fraction 3. This protocol shows that sonication breaks down α-synuclein insoluble complexes from the fly brain, making them soluble in the SDS buffer and enriching fraction 2 of the protocol.
Collapse
Affiliation(s)
- Khondamir Imomnazarov
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
| | - Joshua Lopez-Scarim
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
| | - Ila Bagheri
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
| | - Valerie Joers
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
| | - Malú Gámez Tansey
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
- Fixel Institute for Neurological Diseases, University of Florida
| | - Alfonso Martín-Peña
- Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute
| |
Collapse
|
3
|
Bolshakova OI, Borisenkova AA, Golomidov IM, Komissarov AE, Slobodina AD, Ryabova EV, Ryabokon IS, Latypova EM, Slepneva EE, Sarantseva SV. Fullerenols Prevent Neuron Death and Reduce Oxidative Stress in Drosophila Huntington's Disease Model. Cells 2022; 12:cells12010170. [PMID: 36611963 PMCID: PMC9818496 DOI: 10.3390/cells12010170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 12/23/2022] [Accepted: 12/28/2022] [Indexed: 01/04/2023] Open
Abstract
Huntington's disease (HD) is one of the human neurodegenerative diseases for which there is no effective treatment. Therefore, there is a strong demand for a novel neuroprotective agent that can alleviate its course. Fullerene derivatives are considered to be such agents; however, they need to be comprehensively investigated in model organisms. In this work, neuroprotective activity of C60(OH)30 and C120O(OH)44 fullerenols was analyzed for the first time in a Drosophila transgenic model of HD. Lifespan, behavior, oxidative stress level and age-related neurodegeneration were assessed in flies with the pathogenic Huntingtin protein expression in nerve cells. Feed supplementation with hydroxylated C60 fullerene and C120O dimer oxide molecules was shown to diminish the oxidative stress level and neurodegenerative processes in the flies' brains. Thus, fullerenes displayed neuroprotective activity in this model.
Collapse
|
4
|
Golomidov IM, Latypova EM, Ryabova EV, Bolshakova OI, Komissarov AE, Sarantseva SV. Reduction of the α-synuclein expression promotes slowing down early neuropathology development in the Drosophila model of Parkinson's disease. J Neurogenet 2022; 36:1-10. [PMID: 35467466 DOI: 10.1080/01677063.2022.2064462] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Parkinson's disease (PD) is a neurodegenerative disease characterised by the formation of Lewy bodies and progressive loss of dopaminergic (DA) neurons in the substantia nigra. Lewy bodies mainly consist of α-synuclein, which plays a critical role in the pathophysiology of PD. The α-synuclein is encoded by the SNCA gene and is the first identified gene associated with hereditary PD. Currently, there are at least six disease-associated mutations in α-synuclein that cause dominantly inherited familial forms of PD. Targeted expression of human SNCA.WT/SNCA.A30P/SNCA.A53T gene in Drosophila melanogaster over specific times employing a temperature-dependent UAS/GAL4 - GAL80 system allows for the evaluation of neurodegenerative processes. In this study, SNCA was expressed only in the adult stage of Drosophila development for 1 or 2 weeks, followed by repression of gene expression for the rest of the fly's life. It was demonstrated that the level of pathology significantly depends on the duration of α-synuclein expression. SNCA gene expression over a longer period of time caused the death of DA neurons, decreased levels of dopamine and locomotor ability. In this case, the observed neurodegenerative processes correlated with the accumulation of α-synuclein in the Drosophila brain. Importantly, repression of α-synuclein expression led to elimination of the soluble protein fraction, in contrast to the insoluble fraction. No further significant development of characteristic signs of pathology was observed after the α-synuclein expression was blocked. Thus, we suggest that reduction of α-synuclein expression alone contributes to slowing down the development of PD-like symptoms.
Collapse
Affiliation(s)
- Ilia M Golomidov
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| | - Evgenia M Latypova
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| | - Elena V Ryabova
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| | - Olga I Bolshakova
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| | - Artem E Komissarov
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| | - Svetlana V Sarantseva
- Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Gatchina, Russia
| |
Collapse
|
5
|
Yeast red pigment, protein aggregates, and amyloidoses: a review. Cell Tissue Res 2022; 388:211-223. [PMID: 35258715 DOI: 10.1007/s00441-022-03609-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 02/26/2022] [Indexed: 11/02/2022]
Abstract
Estimating the amyloid level in yeast Saccharomyces, we found out that the red pigment (product of polymerization of aminoimidazole ribotide) accumulating in ade1 and ade2 mutants leads to drop of the amyloid content. We demonstrated in vitro that fibrils of several proteins grown in the presence of the red pigment stop formation at the protofibril stage and form stable aggregates due to coalescence. Also, the red pigment inhibits reactive oxygen species accumulation in cells. This observation suggests that red pigment is involved in oxidative stress response. We developed an approach to identify the proteins whose aggregation state depends on prion (amyloid) or red pigment presence. These sets of proteins overlap and in both cases involve many different chaperones. Red pigment binds amyloids and is supposed to prevent chaperone-mediated prion propagation. An original yeast-Drosophila model was offered to estimate the red pigment effect on human proteins involved in neurodegeneration. As yeast cells are a natural feed of Drosophila, we could compare the data on transgenic flies fed on red and white yeast cells. Red pigment inhibits aggregation of human Amyloid beta and α-synuclein expressed in yeast cells. In the brain of transgenic flies, the red pigment diminishes amyloid beta level and the area of neurodegeneration. An improvement in memory and viability accompanied these changes. In transgenic flies expressing human α-synuclein, the pigment leads to a decreased death rate of dopaminergic neurons and improves mobility. The obtained results demonstrate yeast red pigment potential for the treatment of neurodegenerative diseases.
Collapse
|
6
|
Shadrina M, Slominsky P. Modeling Parkinson's Disease: Not Only Rodents? Front Aging Neurosci 2021; 13:695718. [PMID: 34421573 PMCID: PMC8377290 DOI: 10.3389/fnagi.2021.695718] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 06/29/2021] [Indexed: 01/12/2023] Open
Abstract
Parkinson’s disease (PD) is a common chronic progressive multifactorial neurodegenerative disease. In most cases, PD develops as a sporadic idiopathic disease. However, in 10%–15% of all patients, Mendelian inheritance of the disease is observed in an autosomal dominant or autosomal recessive manner. To date, mutations in seven genes have been convincingly confirmed as causative in typical familial forms of PD, i.e., SNCA, LRRK2, VPS35, PRKN, PINK1, GBA, and DJ-1. Family and genome-wide association studies have also identified a number of candidate disease genes and a common genetic variability at 90 loci has been linked to risk for PD. The analysis of the biological function of both proven and candidate genes made it possible to conclude that mitochondrial dysfunction, lysosomal dysfunction, impaired exosomal transport, and immunological processes can play important roles in the development of the pathological process of PD. The mechanisms of initiation of the pathological process and its earliest stages remain unclear. The study of the early stages of the disease (before the first motor symptoms appear) is extremely complicated by the long preclinical period. In addition, at present, the possibility of performing complex biochemical and molecular biological studies familial forms of PD is limited. However, in this case, the analysis of the state of the central nervous system can only be assessed by indirect signs, such as the level of metabolites in the cerebrospinal fluid, peripheral blood, and other biological fluids. One of the potential solutions to this problem is the analysis of disease models, in which it is possible to conduct a detailed in-depth study of all aspects of the pathological process, starting from its earliest stages. Many modeling options are available currently. An analysis of studies published in the 2000s suggests that toxic models in rodents are used in the vast majority of cases. However, interesting and important data for understanding the pathogenesis of PD can be obtained from other in vivo models. Within the framework of this review, we will consider various models of PD that were created using various living organisms, from unicellular yeast (Saccharomyces cerevisiae) and invertebrate (Nematode and Drosophila) forms to various mammalian species.
Collapse
Affiliation(s)
- Maria Shadrina
- Laboratory of Molecular Genetics of Hereditary Diseases, Institute of Molecular Genetics of National Research Centre "Kurchatov Institute", Moscow, Russia
| | - Petr Slominsky
- Laboratory of Molecular Genetics of Hereditary Diseases, Institute of Molecular Genetics of National Research Centre "Kurchatov Institute", Moscow, Russia
| |
Collapse
|
7
|
Aman Mohammadi M, Ahangari H, Mousazadeh S, Hosseini SM, Dufossé L. Microbial pigments as an alternative to synthetic dyes and food additives: a brief review of recent studies. Bioprocess Biosyst Eng 2021; 45:1-12. [PMID: 34373951 DOI: 10.1007/s00449-021-02621-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 08/04/2021] [Indexed: 12/21/2022]
Abstract
Synthetic coloring agents have been broadly utilized in several industries such as food, pharmaceuticals, cosmetic and textile. Recent surveys on the potential of teratogenicity and carcinogenicity of synthetic dyes have expressed concerns regarding their use in foods. Worldwide, food industries have need for safe, natural and new colorings to add variety to foods and make them appealing to consumers. Natural colorings not only expand the marketability of the food product, but also add further healthful features such as antibacterial, antioxidant, anticancer and antiviral properties. Novel microbial strains should be explored to meet the increasing global search of natural pigments and suitable techniques must be developed for the marketable production of new pigments, using microbial cultures, viz., fungi, and bacteria. To address the issue of the natural coloring agents, this review presents the recent trends in several studies of microbial pigments, their biological properties and industrial applications.
Collapse
Affiliation(s)
- Masoud Aman Mohammadi
- Student Research Committee, Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hossein Ahangari
- Department of Food Science and Technology, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Saeed Mousazadeh
- Department of Food Science and Technology, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Seyede Marzieh Hosseini
- Student Research Committee, Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Laurent Dufossé
- CHEMBIOPRO Lab, Ecole Supérieure d'Ingénieurs Réunion Océan Indien (ESIROI), Université de La Réunion, Département Agroalimentaire, 97744, Saint-Denis, France.
| |
Collapse
|
8
|
Rapoport A, Guzhova I, Bernetti L, Buzzini P, Kieliszek M, Kot AM. Carotenoids and Some Other Pigments from Fungi and Yeasts. Metabolites 2021; 11:92. [PMID: 33561985 PMCID: PMC7915786 DOI: 10.3390/metabo11020092] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 01/13/2021] [Accepted: 02/03/2021] [Indexed: 12/11/2022] Open
Abstract
Carotenoids are an essential group of compounds that may be obtained by microbiological synthesis. They are instrumental in various areas of industry, medicine, agriculture, and ecology. The increase of carotenoids' demand at the global market is now essential. At the moment, the production of natural carotenoids is more expensive than obtaining their synthetic forms, but several new approaches/directions on how to decrease this difference were developed during the last decades. This review briefly describes the information accumulated until now about the beneficial effects of carotenoids on human health protection, their possible application in the treatments of various diseases, and their use in the food and feed industry. This review also describes some issues that are linked with biotechnological production of fungal and yeasts carotenoids, as well as new approaches/directions to make their biotechnological production more efficient.
Collapse
Affiliation(s)
- Alexander Rapoport
- Laboratory of Cell Biology, Institute of Microbiology and Biotechnology, University of Latvia, Jelgavas Str. 1-537, LV-1004 Riga, Latvia
| | - Irina Guzhova
- Laboratory of Cell Protective Mechanisms, Institute of Cytology, Russian Academy of Sciences, Tikhoretsky Avenue 4, 194064 Saint Petersburg, Russia;
| | - Lorenzo Bernetti
- Department of Agricultural, Food and Environmental Sciences and Industrial Yeasts Collection DBVPG, University of Perugia, Borgo XX Giugno 74, 06121 Perugia, Italy; (L.B.); (P.B.)
| | - Pietro Buzzini
- Department of Agricultural, Food and Environmental Sciences and Industrial Yeasts Collection DBVPG, University of Perugia, Borgo XX Giugno 74, 06121 Perugia, Italy; (L.B.); (P.B.)
| | - Marek Kieliszek
- Department of Food Biotechnology and Microbiology, Institute of Food Sciences, Warsaw University of Life Sciences—SGGW, Nowoursynowska 159C, 02-776 Warsaw, Poland;
| | - Anna Maria Kot
- Department of Food Biotechnology and Microbiology, Institute of Food Sciences, Warsaw University of Life Sciences—SGGW, Nowoursynowska 159C, 02-776 Warsaw, Poland;
| |
Collapse
|
9
|
Chernoff YO, Grizel AV, Rubel AA, Zelinsky AA, Chandramowlishwaran P, Chernova TA. Application of yeast to studying amyloid and prion diseases. ADVANCES IN GENETICS 2020; 105:293-380. [PMID: 32560789 PMCID: PMC7527210 DOI: 10.1016/bs.adgen.2020.01.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Amyloids are fibrous cross-β protein aggregates that are capable of proliferation via nucleated polymerization. Amyloid conformation likely represents an ancient protein fold and is linked to various biological or pathological manifestations. Self-perpetuating amyloid-based protein conformers provide a molecular basis for transmissible (infectious or heritable) protein isoforms, termed prions. Amyloids and prions, as well as other types of misfolded aggregated proteins are associated with a variety of devastating mammalian and human diseases, such as Alzheimer's, Parkinson's and Huntington's diseases, transmissible spongiform encephalopathies (TSEs), amyotrophic lateral sclerosis (ALS) and transthyretinopathies. In yeast and fungi, amyloid-based prions control phenotypically detectable heritable traits. Simplicity of cultivation requirements and availability of powerful genetic approaches makes yeast Saccharomyces cerevisiae an excellent model system for studying molecular and cellular mechanisms governing amyloid formation and propagation. Genetic techniques allowing for the expression of mammalian or human amyloidogenic and prionogenic proteins in yeast enable researchers to capitalize on yeast advantages for characterization of the properties of disease-related proteins. Chimeric constructs employing mammalian and human aggregation-prone proteins or domains, fused to fluorophores or to endogenous yeast proteins allow for cytological or phenotypic detection of disease-related protein aggregation in yeast cells. Yeast systems are amenable to high-throughput screening for antagonists of amyloid formation, propagation and/or toxicity. This review summarizes up to date achievements of yeast assays in application to studying mammalian and human disease-related aggregating proteins, and discusses both limitations and further perspectives of yeast-based strategies.
Collapse
Affiliation(s)
- Yury O Chernoff
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, United States; Laboratory of Amyloid Biology, St. Petersburg State University, St. Petersburg, Russia.
| | - Anastasia V Grizel
- Laboratory of Amyloid Biology, St. Petersburg State University, St. Petersburg, Russia
| | - Aleksandr A Rubel
- Laboratory of Amyloid Biology, St. Petersburg State University, St. Petersburg, Russia; Department of Genetics and Biotechnology, St. Petersburg State University, St. Petersburg, Russia; Sirius University of Science and Technology, Sochi, Russia
| | - Andrew A Zelinsky
- Laboratory of Amyloid Biology, St. Petersburg State University, St. Petersburg, Russia
| | | | - Tatiana A Chernova
- Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, United States
| |
Collapse
|
10
|
Golomidov I, Bolshakova O, Komissarov A, Sharoyko V, Slepneva Е, Slobodina A, Latypova E, Zherebyateva O, Tennikova T, Sarantseva S. The neuroprotective effect of fullerenols on a model of Parkinson's disease in Drosophila melanogaster. Biochem Biophys Res Commun 2019; 523:446-451. [PMID: 31879013 DOI: 10.1016/j.bbrc.2019.12.075] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 12/16/2019] [Indexed: 01/03/2023]
Abstract
Neuroprotective properties of fullerenols С60(OH)30 and С70(OH)30 have been shown in a Drosophila melanogaster model of Parkinson's Disease (PD). Fullerenols used in this work demonstrated negligible toxicity even at high concentrations as a result of a specifically developed manufacturing process. It has been shown that the drugs promote restoration of dopamine levels, reduce oxidative stress in transgenic flies expressing the human alpha-synuclein gene, prevent death of dopaminergic neurons in the brain and alleviate aggregation of alpha-synuclein. Thus, the anti-aggregation effect of fullerenols, demonstrated for various forms of amyloid proteins, is also observed for alpha-synuclein, resulting in reduction of formation of insoluble aggregates of this protein. Neuroprotective activity was affected by the Drosophila melanogaster genotype and not by the number of carbon atoms in the fullerenol compounds. We concluded that due to their unique properties, fullerenols might be a promising tool for drug development to treat PD.
Collapse
Affiliation(s)
- I Golomidov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | - O Bolshakova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | - A Komissarov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | - V Sharoyko
- Institute of Chemistry, Saint-Petersburg State University, Saint-Petersburg, Russia
| | - Е Slepneva
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | - A Slobodina
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | - E Latypova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia
| | | | - T Tennikova
- Institute of Chemistry, Saint-Petersburg State University, Saint-Petersburg, Russia
| | - S Sarantseva
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre, Kurchatov Institute, Gatchina, Russia.
| |
Collapse
|